Cargando…
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
BACKGROUND: Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries. PATIENTS AND METHODS: In this randomised, open-label, phase III tri...
Autores principales: | Guo, Y, Ahn, M -J, Chan, A, Wang, C -H, Kang, J -H, Kim, S -B, Bello, M, Arora, R S, Zhang, Q, He, X, Li, P, Dechaphunkul, A, Kumar, V, Kamble, K, Li, W, Kandil, A, Cohen, E E W, Geng, Y, Zografos, E, Tang, P Z |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927323/ https://www.ncbi.nlm.nih.gov/pubmed/31501887 http://dx.doi.org/10.1093/annonc/mdz388 |
Ejemplares similares
-
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)
por: Clement, P. M., et al.
Publicado: (2016) -
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
por: Machiels, Jean-Pascal H, et al.
Publicado: (2014) -
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
por: Cohen, E. E. W., et al.
Publicado: (2017) -
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)
por: Seiwert, T. Y., et al.
Publicado: (2014) -
Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.
por: Braakhuis, B. J., et al.
Publicado: (1983)